These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 8352177)
1. Effect of cigarette smoking on coronary patency after thrombolytic therapy for myocardial infarction. TEAM-2 Investigators. Second Multicenter Thrombolytic Trials of Eminase in Acute Myocardial Infarction. Gomez MA; Karagounis LA; Allen A; Anderson JL Am J Cardiol; 1993 Aug; 72(5):373-8. PubMed ID: 8352177 [TBL] [Abstract][Full Text] [Related]
2. Does thrombolysis in myocardial infarction (TIMI) perfusion grade 2 represent a mostly patent artery or a mostly occluded artery? Enzymatic and electrocardiographic evidence from the TEAM-2 study. Second Multicenter Thrombolysis Trial of Eminase in Acute Myocardial Infarction. Karagounis L; Sorensen SG; Menlove RL; Moreno F; Anderson JL J Am Coll Cardiol; 1992 Jan; 19(1):1-10. PubMed ID: 1729317 [TBL] [Abstract][Full Text] [Related]
3. Incomplete recanalization as an important determinant of Thrombolysis in Myocardial Infarction (TIMI) grade 2 flow after thrombolytic therapy for acute myocardial infarction. TEAM Investigators. Thrombolytic Trial of Eminase in Acute Myocardial Infarction. Zahger D; Karagounis LA; Cercek B; Anderson JL; Sorensen S; Moreno F; Shah PK Am J Cardiol; 1995 Oct; 76(11):749-52. PubMed ID: 7572648 [TBL] [Abstract][Full Text] [Related]
4. Effect of cigarette smoking on outcome after thrombolytic therapy for myocardial infarction. Grines CL; Topol EJ; O'Neill WW; George BS; Kereiakes D; Phillips HR; Leimberger JD; Woodlief LH; Califf RM Circulation; 1995 Jan; 91(2):298-303. PubMed ID: 7805231 [TBL] [Abstract][Full Text] [Related]
5. Influence of cigarette smoking on rate of reopening of the infarct-related coronary artery after myocardial infarction: a multivariate analysis. de Chillou C; Riff P; Sadoul N; Ethevenot G; Feldmann L; Isaaz K; Simon JP; Boursier M; Khalifé K; Thisse JY; Aliot E J Am Coll Cardiol; 1996 Jun; 27(7):1662-8. PubMed ID: 8636551 [TBL] [Abstract][Full Text] [Related]
6. Effects of early thrombolytic therapy (anistreplase versus streptokinase) on enzymatic and electrocardiographic infarct size in acute myocardial infarction. TEAM-2 Investigators. Karagounis L; Moreno F; Menlove RL; Ipsen S; Anderson JL Am J Cardiol; 1991 Oct; 68(9):848-56. PubMed ID: 1927942 [TBL] [Abstract][Full Text] [Related]
7. Multicenter patency trial of intravenous anistreplase compared with streptokinase in acute myocardial infarction. The TEAM-2 Study Investigators. Anderson JL; Sorensen SG; Moreno FL; Hackworthy RA; Browne KF; Dale HT; Leya F; Dangoisse V; Eckerson HW; Marder VJ Circulation; 1991 Jan; 83(1):126-40. PubMed ID: 1984877 [TBL] [Abstract][Full Text] [Related]
8. Clinical predictors of early infarct-related artery patency following thrombolytic therapy: importance of body weight, smoking history, infarct-related artery and choice of thrombolytic regimen: the GUSTO-I experience. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. Lundergan CF; Reiner JS; McCarthy WF; Coyne KS; Califf RM; Ross AM J Am Coll Cardiol; 1998 Sep; 32(3):641-7. PubMed ID: 9741505 [TBL] [Abstract][Full Text] [Related]
9. Multivariate associates of QT dispersion in patients with acute myocardial infarction: primacy of patency status of the infarct-related artery. TEAM-3 Investigators. Third trial of Thrombolysis with Eminase in Acute Myocardial Infarction. Karagounis LA; Anderson JL; Moreno FL; Sorensen SG Am Heart J; 1998 Jun; 135(6 Pt 1):1027-35. PubMed ID: 9630107 [TBL] [Abstract][Full Text] [Related]
10. TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction. Ventriculographic, enzymatic, and electrocardiographic evidence from the TEAM-3 Study. Anderson JL; Karagounis LA; Becker LC; Sorensen SG; Menlove RL Circulation; 1993 Jun; 87(6):1829-39. PubMed ID: 8504495 [TBL] [Abstract][Full Text] [Related]
11. Gender and acute myocardial infarction: is there a different response to thrombolysis? Woodfield SL; Lundergan CF; Reiner JS; Thompson MA; Rohrbeck SC; Deychak Y; Smith JO; Burton JR; McCarthy WF; Califf RM; White HD; Weaver WD; Topol EJ; Ross AM J Am Coll Cardiol; 1997 Jan; 29(1):35-42. PubMed ID: 8996292 [TBL] [Abstract][Full Text] [Related]
12. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. Simes RJ; Topol EJ; Holmes DR; White HD; Rutsch WR; Vahanian A; Simoons ML; Morris D; Betriu A; Califf RM Circulation; 1995 Apr; 91(7):1923-8. PubMed ID: 7895348 [TBL] [Abstract][Full Text] [Related]
13. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. Cannon CP; McCabe CH; Diver DJ; Herson S; Greene RM; Shah PK; Sequeira RF; Leya F; Kirshenbaum JM; Magorien RD J Am Coll Cardiol; 1994 Dec; 24(7):1602-10. PubMed ID: 7963104 [TBL] [Abstract][Full Text] [Related]
14. Independent impact of thrombolytic therapy and vessel patency on left ventricular dilation after myocardial infarction. Serial echocardiographic follow-up. Popović AD; Nesković AN; Babić R; Obradović V; Bozinović L; Marinković J; Lee JC; Tan M; Thomas JD Circulation; 1994 Aug; 90(2):800-7. PubMed ID: 8044951 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of streptokinase, but not tissue-type plasminogen activator, in achieving 90-minute patency after thrombolysis for acute myocardial infarction decreases with time to treatment. PERM Study Group. Prospective Evaluation of Reperfusion Markers. Steg PG; Laperche T; Golmard JL; Juliard JM; Benamer H; Himbert D; Aubry P J Am Coll Cardiol; 1998 Mar; 31(4):776-9. PubMed ID: 9525545 [TBL] [Abstract][Full Text] [Related]
16. Lack of influence of pretreatment antistreptokinase antibody on efficacy in a multicenter patency comparison of intravenous streptokinase and anistreplase in acute myocardial infarction. Fears R; Hearn J; Standring R; Anderson JL; Marder VJ Am Heart J; 1992 Aug; 124(2):305-14. PubMed ID: 1636574 [TBL] [Abstract][Full Text] [Related]
17. Angiographically assessed coronary arterial patency and reocclusion in patients with acute myocardial infarction treated with anistreplase: results of the anistreplase reocclusion multicenter study (ARMS). Relik-van Wely L; Visser RF; van der Pol JM; Bartholomeus I; Couvée JE; Drost H; Vet AJ; Klomps HC; van Ekelen WA; van den Berg F Am J Cardiol; 1991 Aug; 68(4):296-300. PubMed ID: 1858670 [TBL] [Abstract][Full Text] [Related]
18. [Indirect criteria of coronary reperfusion and permeability in patients with acute myocardial infarction who have received thrombolytic therapy]. Pereira MA; Albuquerque A; Azevedo JG; Torres S; Gomes L; Campos M; Pimenta A Rev Port Cardiol; 1991 Mar; 10(3):229-35. PubMed ID: 1854515 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: mechanism of the "smoker's paradox" from the GUSTO-I trial, with angiographic insights. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries. Barbash GI; Reiner J; White HD; Wilcox RG; Armstrong PW; Sadowski Z; Morris D; Aylward P; Woodlief LH; Topol EJ J Am Coll Cardiol; 1995 Nov; 26(5):1222-9. PubMed ID: 7594035 [TBL] [Abstract][Full Text] [Related]
20. Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. Woodfield SL; Lundergan CF; Reiner JS; Greenhouse SW; Thompson MA; Rohrbeck SC; Deychak Y; Simoons ML; Califf RM; Topol EJ; Ross AM J Am Coll Cardiol; 1996 Dec; 28(7):1661-9. PubMed ID: 8962549 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]